Take the Tip of the Tongue Trivia Challenge
Metozolv ODT treats diabetic gastroparesis and refractory GERD1 and rapidly* melts on the tongue, so you don't need to take it with liquid.
See if you can answer these tongue trivia questions before they disintegrate. Click below to play.
Challenge a friend
Challenge a friend to play the Tip of the Tongue Trivia Challenge, and tell your friend about Metozolv ODT—a convenient, orally disintegrating tablet treatment for diabetic gastroparesis and refractory GERD.1
*
Please enter the words in the image to prevent automated spam submissions.
Learn more about Metozolv ODT
Discover the benefits of Metozolv ODT, a convenient form of metoclopramide, by reading through the Metozolv ODT web site. If you have any questions, ask your healthcare professional for additional information.
Learn more about Metozolv ODT
Is Metozolv ODT right for you?
Discover valuable tools and resources about diabetic gastroparesis, refractory GERD, and Metozolv ODT
*Metozolv ODT disintegrates on the tongue in a median of 53.5 seconds (mean ± standard deviation, 76.8 ± 110.6 seconds).1
Reference: 1. METOZOLV ODT [package insert]. Morrisville, NC: Salix Pharmaceuticals, Inc; 2009.
IMPORTANT SAFETY INFORMATION
Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive
dyskinesia increases with the duration of treatment and the total cumulative dose.
Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive
dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.
Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh
the risk of developing tardive dyskinesia.
METOZOLV™ ODT (metoclopramide HCl) is indicated as short-term therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD)
who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric
stasis) in adults. Therapy should not exceed 12 weeks in duration. METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage,
or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal
reactions. METOZOLV ODT should be used with caution in patients showing acute dystonic reactions, drug-induced Parkinsonism, or other extrapyramidal symptoms;
neuroleptic malignant syndrome; with a prior history of depression; hypertension; congestive heart failure and ventricular arrhythmia. Patients may experience
withdrawal symptoms after stopping the use of METOZOLV ODT.
In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.
Please see accompanying full Prescribing Information
for Metozolv ODT, including BOXED WARNING.